p57 Inhibitors
Common p57 Inhibitors include, but are not limited to PHA-793887 CAS 718630-59-2, Dinaciclib CAS 779353-01-4, AT7519 CAS 844442-38-2, AZD 5438 CAS 602306-29-6 and PHA-793887 CAS 718630-59-2.
p57 inhibitors belong to a specific chemical class of compounds designed to target and inhibit the activity of p57, also known as cyclin-dependent kinase inhibitor 1C (CDKN1C). p57 is a cell cycle regulator that plays a crucial role in controlling cell division and proliferation. It belongs to the cyclin-dependent kinase inhibitor family, which functions to halt cell cycle progression and hinders uncontrolled cell growth.
p57 inhibitors work by specifically targeting the p57 protein, interfering with its ability to bind to and inhibit cyclin-dependent kinases, which are essential for cell cycle progression. By doing so, these inhibitors may modulate the cell cycle machinery, influencing the timing and regulation of cell division. Research into p57 inhibitors is ongoing to unravel their precise mechanisms of action and explore their implications in understanding cell cycle regulation. The study of p57 inhibitors contributes to a deeper understanding of the intricate mechanisms governing cell proliferation and the maintenance of cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK4 and CDK6, preventing their interaction with cyclin D and halting cell cycle progression. Inhibiting CDK4/6 disrupts the G1 to S phase transition, slowing down cell proliferation. Palbociclib has been studied for cancers with dysregulated p57 and cell cycle control. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib also targets CDK4 and CDK6, blocking their activity in complex with cyclin D. By impeding G1 to S phase progression, Ribociclib slows cell proliferation. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
LY2835219 is an investigational CDK4/6 inhibitor that blocks their interaction with cyclin D1, causing cell cycle arrest. Its activity in inhibiting CDK4/6 could affect the proliferation of cells with p57 alterations, providing potential benefits in relevant cancer types. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
PHA-793887 is a potent CDK inhibitor targeting CDK1, CDK2, CDK4, and CDK6. It hinders cell cycle progression and division by inhibiting these kinases, which could affect the proliferation and growth of cells that express CDKN1C. PHA-793887's broad CDK inhibitory profile could impact various cellular processes. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib inhibits CDK1, CDK2, CDK5, and CDK9. By targeting these kinases, Dinaciclib can disrupt various aspects of cell cycle regulation, proliferation, and transcription. Its impact on p57-expressing cells might alter their cell cycle progression and gene expression patterns. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 is a multi-CDK inhibitor targeting CDK1, CDK2, CDK4, CDK5, and CDK9. Inhibiting these CDKs can lead to cell cycle arrest and reduced transcriptional activity. AT7519's broad CDK inhibitory effects could influence various cellular processes in p57-expressing cells, potentially impacting growth and survival. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a CDK inhibitor with activity against CDK1, CDK2, CDK7, and CDK9. It can disrupt cell cycle progression and transcriptional regulation. By inhibiting these CDKs, SNS-032 might affect cell growth and gene expression patterns in CDKN1C-expressing cells, potentially leading to growth inhibition. | ||||||
Zotiraciclib | 937270-47-8 | sc-507450 | 10 mg | $202.00 | ||
This compound, also called TG-02, is a multi-CDK inhibitor targeting CDK1, CDK2, CDK5, CDK7, and CDK9. Its inhibitory effects on these CDKs can impact cell cycle progression, transcription, and other cellular processes. TG-02's activity against CDKs might influence growth and survival in cells expressing p57. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is a CDK inhibitor that targets CDK1, CDK2, and CDK9. By inhibiting these CDKs, AZD5438 can affect cell cycle progression, transcription, and other processes. Its impact on p57-expressing cells might lead to alterations in growth, gene expression, and overall cellular behavior. | ||||||